Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.64 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.40 |
| ▸ | PGAM1 | P18669 | 1/20 | 0.39 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.37 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.37 |
| ▸ | TYR | P14679 | 2/20 | 0.36 |
| ▸ | HMGCR | P04035 | 1/20 | 0.36 |
| ▸ | CA12 | O43570 | 1/20 | 0.36 |
| ▸ | CA1 | P00915 | 1/20 | 0.36 |
| ▸ | CA9 | Q16790 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 2/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
| ▸ | CNR1 | P21554 | 1/20 | 0.34 |
| ▸ | CNR2 | P34972 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11703055 | 0.86 | TAAR1 (0.48) | TAAR1PTGS2CYP3A4PGAM1PTPN1 | |
| SCHEMBL9854552 | 0.80 | TAAR1 (0.70) | TAAR1PTGS2CYP3A4TYRCA12 | |
| SCHEMBL10193863 | 0.80 | TAAR1 (0.40) | TAAR1HMGCRHPGDRAB9ACNR1 | |
| SCHEMBL16693755 | 0.80 | TAAR1 (0.56) | TAAR1PTGS2CYP3A4CA12CA1 | |
| SCHEMBL24096195 | 0.78 | TAAR1 (1.00) | TAAR1CYP3A4CA12CA1CA9 | |
| SCHEMBL26938483 | 0.78 | TAAR1 (0.39) | TAAR1HTTNPC1HPGDMAPK1 | |
| SCHEMBL12184907 | 0.76 | TAAR1 (0.42) | TAAR1NPC1RAB9ATP53TSHR | |
| SCHEMBL8422938 | 0.76 | TAAR1 (0.38) | TAAR1HPGD | |
| SCHEMBL23451053 | 0.76 | TAAR1 (0.64) | TAAR1TYRCA12CA1CA9 | |
| SCHEMBL22011182 | 0.76 | PTPN1 (0.46) | TAAR1PTGS2CYP3A4PTPN1PTPN11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10316028-B2 | Orexin receptor antagonists | HEPTARES THERAPEUTICS LIMITED (GB) | 2019-06-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10316028-B2 | Orexin receptor antagonists | HCRTR2, HCRTR1, NPY4R | TAAR1 78/4885PTGS2 3036/4885CYP3A4 2076/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.